menu
    • menu

    Company profile for Luminopia

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Luminopia is a software-only digital therapeutic designed to be used with commercially available Head-Mounted Displays (HMDs) which are compatible with the software application. Luminopia is indicated for improvement in visual acuity in amblyopia patients, aged 4-7, associated with anisometropia and/or with mild strabismus, having received treatment instructions (frequency and duration) as prescribed by a trained eye-care prof...
    Luminopia is a software-only digital therapeutic designed to be used with commercially available Head-Mounted Displays (HMDs) which are compatible with the software application. Luminopia is indicated for improvement in visual acuity in amblyopia patients, aged 4-7, associated with anisometropia and/or with mild strabismus, having received treatment instructions (frequency and duration) as prescribed by a trained eye-care professional. Luminopia is intended for both previously treated and untreated patients; however, patients with more than 12 months of prior treatment (other than refractive correction) have not been studied.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    LuminopiaUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    625 Massachusetts Ave, Cambridge, Massachusetts 02139
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://luminopia.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/luminopia
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Luminopia Shows Promise in Exotropia Pilot Study
    Luminopia Shows Promise in Exotropia Pilot Study

    25 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/luminopia-shows-promise-in-improving-control-of-intermittent-exotropia-in-pilot-study-302724282.html

    PR NEWSWIRE
    25 Mar 2026
    Share Share
    Luminopia Acknowledged On Fast Company Tech Innovators List
    Luminopia Acknowledged On Fast Company Tech Innovators List

    14 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/luminopia-recognized-on-fast-companys-next-big-things-in-tech-list-302583094.html

    PR NEWSWIRE
    14 Oct 2025
    Share Share
    Luminopia Recognized On TIME's Top Healthtech Companies List 2025
    Luminopia Recognized On TIME's Top Healthtech Companies List 2025

    08 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/luminopia-awarded-on-times-list-of-the-worlds-top-healthtech-companies-2025-302577827.html

    PR NEWSWIRE
    08 Oct 2025
    Share Share
    Luminopia scores $16M for virtual reality-based lazy eye treatment
    Luminopia scores $16M for virtual reality-based lazy eye treatment

    27 Jun 2023

    // Nicole DeFeudis ENDPTS

    https://endpts.com/luminopia-scores-16m-for-virtual-reality-based-lazy-eye-treatment/

    Nicole DeFeudis ENDPTS
    27 Jun 2023
    Share Share
    Luminopia, Inc. Announces Closing of Oversubscribed Series A Financing Round
    Luminopia, Inc. Announces Closing of Oversubscribed Series A Financing Round

    27 Jun 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230627252505/en

    BUSINESSWIRE
    27 Jun 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search